Leumye™ analyses mutations and selected translocations in 90 key genes in myeloid neoplasm by targeted DNA sequencing (Leumye™ D), or in combination with whole transcriptome mRNA sequencing (Leumye™ DR) to detect a broader range of gene translocations and expression changes.
WHO IS IT FOR
All patients with myeloid neoplasms
Acute myeloid leukemia (AML) and related neoplasms
Myelodysplastic syndromes (MDS)
Myeloproliferative neoplasms (MPN)
MDS/MPN
SAMPLE TYPE
Peripheral blood or bone marrow